Abaxis upgraded to Hold from Sell at Feltl Feltl upgraded Abaxis to Hold following the company's Q4 report, noting that the company believes it has worked through its channel issues. The firm raised its price target on the shares to $38.50 from $33.75.
News For ABAX From The Last 14 Days
Check below for free stories on ABAX the last two weeks.
Life Sciences highlights this week at Canaccord Canaccord highlighted six diagnostic names that report this week and recommends buying Top Pick IDEXX (IDXX) into the print given strong recurring razor/razorblade sales and consistent organic growth. The analyst expects Hold rated Quest Diagnostics (DGX) to report upside to Street estimates of $1.06/$1.882B, Quidel (QDEL) to have an uneventful report, Exact Sciences (EXAS) to provide an update on numerous catalysts near-term and Abaxis (ABAX) to report earnings below consensus. Lastly, the firm is cautious on Meridian Bioscience (VIVO) following a competitor report last week.